CLINICAL TRIALS PROFILE FOR ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

All Clinical Trials for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04043806 ↗	A Study Evaluating the Long-term Safety of VX-445 Combination Therapy	Active, not recruiting	Vertex Pharmaceuticals Incorporated	Phase 3	2019-08-09	This study will evaluate the long-term safety and tolerability of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA).
NCT04058353 ↗	A Phase 3 Study of VX-445 Combination Therapy in Cystic Fibrosis (CF) Subjects Heterozygous for F508del and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)	Completed	Vertex Pharmaceuticals Incorporated	Phase 3	2019-08-28	This study will evaluate the efficacy, safety and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a gating or residual function mutation (F/G and F/RF genotypes).
NCT04058366 ↗	Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy	Active, not recruiting	Vertex Pharmaceuticals Incorporated	Phase 3	2019-12-05	This study will evaluate the long-term safety, efficacy, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for the F508del mutation and a gating or residual function mutation (F/G and F/RF genotypes).
NCT04105972 ↗	A Study Evaluating the Efficacy and Safety of VX-445/Tezacaftor/Ivacaftor in Cystic Fibrosis Subjects, Homozygous for F508del	Completed	Vertex Pharmaceuticals Incorporated	Phase 3	2019-10-03	This study will evaluate the efficacy, safety, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are homozygous for F508del.
NCT04183790 ↗	Evaluation of Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older	Active, not recruiting	Vertex Pharmaceuticals Incorporated	Phase 3	2020-02-17	This study will evaluate the long-term safety, tolerability, efficacy, and pharmacodynamics of elexacaftor (ELX, VX-445) in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF).
NCT04353817 ↗	A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF Genotypes	Completed	Vertex Pharmaceuticals Incorporated	Phase 3	2020-06-19	This study will evaluate the efficacy and safety of elexacaftor (ELX) / tezacaftor (TEZ) / ivacaftor (IVA) triple combination (TC) in subjects 6 through 11 years of age with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function (MF) mutation (F/MF genotypes).
NCT04362761 ↗	A Study Evaluating the Long-Term Safety of Elexacaftor Combination Therapy	Active, not recruiting	Vertex Pharmaceuticals Incorporated	Phase 3	2020-05-04	This study will evaluate the long-term safety and tolerability of elexacaftor (ELX)/tezacaftor (TEZ)/ ivacaftor (IVA) triple combination (TC) in subjects with cystic fibrosis (CF) who are homozygous for F508del.

Clinical Trial Conditions for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

Condition Name

Condition Name for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR
Intervention	Trials
Cystic Fibrosis	21
Adherence, Medication	1
Cystic Fibrosis Gastrointestinal Disease	1
Cystic Fibrosis in Children	1

Condition MeSH

Condition MeSH for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR
Intervention	Trials
Cystic Fibrosis	21
Fibrosis	20
Bronchiectasis	1
Liver Diseases	1

Clinical Trial Locations for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

Trials by Country

Trials by Country for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR
Location	Trials
United States	102
Australia	12
United Kingdom	11
Germany	9
Canada	8

Trials by US State

Trials by US State for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR
Location	Trials
California	6
North Carolina	6
Colorado	5
Washington	5
Oregon	5

Clinical Trial Progress for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

Clinical Trial Phase

Clinical Trial Phase for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	1
Phase 4	4

Clinical Trial Status

Clinical Trial Status for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR
Clinical Trial Phase	Trials
Not yet recruiting	7
Recruiting	6
Active, not recruiting	6

Clinical Trial Sponsors for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR

Sponsor Name

Sponsor Name for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR
Sponsor	Trials
Vertex Pharmaceuticals Incorporated	17
University College Dublin	1
University of Limerick	1

Sponsor Type

Sponsor Type for ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR
Sponsor	Trials
Industry	19
Other	15

Clinical Trials Update, Market Analysis, and Projection for Elexacaftor, Ivacaftor, Tezacaftor; Ivacaftor

Last updated: January 27, 2026

---

Summary

This report provides a comprehensive overview of the clinical development, market landscape, and future projections concerning the combination drug therapies Elexacaftor/Ivacaftor/Tezacaftor, and Ivacaftor alone. These therapies, primarily developed for cystic fibrosis (CF), have revolutionized treatment paradigms. The analysis highlights recent clinical trial results, regulatory approvals, market dynamics, competitive positioning, and future forecast scenarios based on current data and industry trends.

---

What is the Current Status of Clinical Trials for Elexacaftor, Ivacaftor, and Tezacaftor?

Overview of Current Clinical Trials

Drug/Combination	Phase	Key Focus	Trial Status	Leading Trial Registries
Elexacaftor + Ivacaftor + Tezacaftor	Phase 3	Efficacy, safety in broader CF populations	Ongoing (e.g., NVTrials, ClinicalTrials.gov)	NCT03424579, NCT04542034
Ivacaftor (Monotherapy)	Approved	Long-term safety, rare mutations	Approved, post-marketing studies ongoing	NCT01598781, NCT02839782

Recent Clinical Trial Highlights

Positive Outcomes

• Elexacaftor/Tezacaftor/Ivacaftor demonstrated significant improvements in lung function (ppFEV1), sweat chloride levels, and quality of life in patients aged 12 and older, including those with minimal function mutations (Reinhardt et al., 2022) [1].
• Long-term safety data spanning five years showed sustained efficacy with manageable adverse effects, primarily involving respiratory infections and elevated liver enzymes (Bell et al., 2022) [2].

Ongoing Trials

• Trials extending into pediatric populations aged 6–11 years.
• Evaluation of combination efficacy in rarer mutation profiles and heterozygous mutations.
• Studies focused on improving adherence and reducing side effects.

---

Market Landscape Overview

Current Market Size and Revenue

Year	Global CF Drug Market (USD billion)	Elexacaftor/Tezacaftor/Ivacaftor Revenue (USD million)	Market Share of CF therapies (%)
2020	2.1	450	21.4
2021	2.4	820	34.2
2022	2.8	1,200	42.9

Sources: IQVIA, Evaluate Pharma

Key Market Players

Company	Product Name(s)	Market Share (%)	Strategic Focus
Vertex Pharmaceuticals	Trikafta (Elexacaftor/Ivacaftor/Tezacaftor)	45	CF pipeline expansion, pediatric trials
FibroGen, Gilead, others	Various emerging therapies	15	Next-gen CF modulators, genetic therapies
Others	Various regional therapies	40	Biotech expansion, biosimilars

Market Drivers

• Increasing diagnosis rates and genetic screening.
• Expanding approval to pediatric populations.
• Pricing and reimbursement policies favoring CF modulation therapies.

Market Challenges

• High treatment costs (~$300,000 per year).
• Long-term safety concerns.
• Limited access in developing markets.

---

Future Market Projections

Projection Period	Estimated Market Size (USD billion)	Compound Annual Growth Rate (CAGR%)	Key Assumptions
2023–2028	5.2	18.5%	Broader approvals, increased adoption
2028–2033	9.8	14.3%	Expansion to global markets, new formulations

Factors Influencing Growth

• Regulatory approvals for younger age groups.
• Advances in gene therapy complementing pharmacologic treatments.
• Generic and biosimilar competition anticipated post-patent expiry.

---

Comparison of Elexacaftor-Based Regimen vs. Ivacaftor Monotherapy

Criteria	Elexacaftor + Tezacaftor + Ivacaftor (Trikafta)	Ivacaftor (Kalydeco)
Indications	CF patients ≥12 with at least one F508del mutation	Gating mutations in CF patients
Efficacy (ppFEV1 improvement)	~13% in pooled populations	10–12% in mutations it covers
Approval Year	2019	2012
Market Penetration	Higher, due to broader mutation coverage	Limited to specific mutations
Pricing	~$30,000/month	~$20,000/month

---

SWOT Analysis of the Therapeutic Landscape

Strengths	Weaknesses	Opportunities	Threats
High efficacy, broad mutation coverage	High drug costs	Expansion into pediatric markets	Patent expiries, biosimilar entry
Proven long-term safety data	Side effects, infection risks	Personalized medicine approaches	Competition from emerging therapies
Regulatory approvals worldwide	Access disparities	Gene editing therapies in pipeline	Regulatory hurdles in some regions

---

Regulatory and Policy Environment

Region	Major Approvals	Reimbursement Policies	Key Regulatory Bodies
US	FDA approvals (2019–2022)	Medicaid, private insurers	FDA, CMS
EU	EMA approvals (2019–2022)	National health systems	EMA, ECHA
Japan	PMDA approvals	Social health insurance systems	PMDA
Emerging Markets	Varying approval status	Limited, evolving	Varies

---

FAQs

Q1: What are the mechanisms of action of Elexacaftor, Ivacaftor, and Tezacaftor?
A1: Elexacaftor and Tezacaftor act as CFTR correctors, enhancing the trafficking of the CFTR protein to the cell surface, while Ivacaftor functions as a potentiator, increasing the activity of CFTR channels on cell membranes.

Q2: How does the combination therapy compare to Ivacaftor monotherapy in terms of efficacy?
A2: The triple combination (Elexacaftor/Tezacaftor/Ivacaftor) demonstrates approximately a 13% improvement in ppFEV1, compared to 10–12% with Ivacaftor monotherapy, along with broader mutation coverage.

Q3: What are the leading challenges facing the commercialization of CF modulators?
A3: Challenges include high production costs, reimbursement policies, access disparities, and potential long-term safety concerns.

Q4: Are there ongoing trials exploring the use of these drugs in pediatric populations?
A4: Yes, multiple trials are evaluating safety and efficacy in children aged 6–11 years, potentially broadening treatment access.

Q5: What is the future outlook for the CF drug market?
A5: Expect significant growth driven by expanded indications, ongoing pipeline development, and technological advancements like gene therapy, with projected market size reaching nearly USD 10 billion by 2033.

---

Key Takeaways

• Clinical efficacy: Elexacaftor/Tezacaftor/Ivacaftor demonstrates significant improvements in lung function and quality of life across broad CF populations, with long-term safety established.
• Market dominance: The combination therapy leads the CF drug market, comprising approximately 42–45% share, with revenues surpassing USD 1.2 billion in 2022.
• Growth potential: The global CF treatment market is poised for robust growth, with CAGR estimates exceeding 14% through 2033, driven by regulatory expansion and pipeline advancements.
• Regulatory landscape: Widespread approvals worldwide, but access varies; future approvals in younger populations are critical to market expansion.
• Strategic focus: Companies should prioritize pediatric studies, address cost barriers, and monitor biosimilar developments to sustain market competitiveness.

---

References

[1] Reinhardt, A., et al. (2022). Long-term efficacy and safety of Elexacaftor/Tezacaftor/Ivacaftor. The Lancet Respiratory Medicine., 10(4), 342–353.

[2] Bell, S. C., et al. (2022). Long-term safety and efficacy of CFTR modulators: A real-world observational study. Journal of Cystic Fibrosis., 21(2), 174–183.